Immunic (IMUX) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunic is the larger company by market cap ($111.7 million vs $99.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | PLYX |
|---|---|---|
| Share price | $8.19 | $2.00 |
| Market cap | $111.75M | $99.69M |
| 1-day change | +8.33% | 0.00% |
| YTD return | +53.37% | — |
| 1-year return | -10.98% | — |
| 5-year return | -90.55% | — |
| EPS (TTM) | $-3.83 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.43 | $48.91 |
| 52-week low | $5.06 | $1.85 |
| Distance from 52-week high | -53.01% | -95.91% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +426.13% | +275.00% |
| Average volume | 284.68K | 76.41K |
| Shares outstanding | 13.64M | 49.85M |
| Employees | 100 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
IMUX vs PLYX FAQ
Which is bigger, Immunic or Polaryx Therapeutics?
Immunic (IMUX) is larger, with a market capitalization of $111.75M compared with $99.69M for Polaryx Therapeutics (PLYX).
Are Immunic and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.